AstraZeneca share price up 15 per cent after Pfizer discloses details of $100 billion bid

LONDON – AstraZeneca shares have jumped 15 per cent in early trading after U.S. pharmaceutical firm Pfizer publicly disclosed details of a $100 billion bid approach.

Pfizer, the maker of Viagra, said Monday that AstraZeneca rejected an initial approach in January valuing the company at about 59 billion pounds ($100 billion). The cash and shares deal would represent a 30 per cent premium on AstraZeneca’s closing share price of 35.26 pounds on Jan. 3, the date of the offer.

Pfizer remains interested and is confident a combination is possible.

The deal comes as drugmakers take advantage of easier financing in a spate of mergers and acquisitions. Swiss drugmaker Novartis AG last week traded its vaccine business for GlaxoSmithKline Plc’s cancer drug business and sold its veterinary drug business to Eli Lilly and Co.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.